APA (7th ed.) Citation

MJ, M., JM, M., K, L., P, H., M, G., MA, C., . . . HI, S. (2022). Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4: 543-52]. European urology oncology, 5(5), 603. https://doi.org/10.1016/j.euo.2022.08.001

Chicago Style (17th ed.) Citation

MJ, Morris, et al. "Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4: 543-52]." European Urology Oncology 5, no. 5 (2022): 603. https://doi.org/10.1016/j.euo.2022.08.001.

MLA (9th ed.) Citation

MJ, Morris, et al. "Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4: 543-52]." European Urology Oncology, vol. 5, no. 5, 2022, p. 603, https://doi.org/10.1016/j.euo.2022.08.001.